ImmunoGen
Inc. (Nasdaq: IMGN) announced that development partner Roche reported
disappointing Phase III MARIANNE study results for three HER2-targeted
regimens to treat HER2-positive metastatic breast cancer. Shares of the biotechnology company plummeted $4.74 to close at $6.11.
Disappointing study results for ImmunoGen
December 19, 2014 at 16:40 PM EST
